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Abstract: This paper reports a RP-HPLC method for the determination of
Lomustine (CCNU) in mouse tumor tissue. CCNU was separated and determined
on a reverse-phase C18 5mm column with a mobile phase of H2O-acetonitrile
(54:46), detected at 254 nm and no internal standard. The calibration curve was
linear (r ¼ 0.9999) within the range of 0.98–15.68mg=ml for CCNU. The recovery
ratio of CCNU was 68.64% (n ¼ 5). The relative standard deviation (RSD) was
0.32%. This method is simple and accurate.
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INTRODUCTION
Lomustine (CCNU) is an alkylating agent, which could combine with the
bases of tumor cells’ nucleic acid by covalent bond, and kill the tumor
cells. Its adaptive diseases are cerebral tumor, malign lymphoma, lung
cancer and malign melanoma. CCNU could be metabolized and elimi-
nated in a short time after oral administration in mice, so ordinary
method of determination could hardly get its content in tumor tissue.
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We found the undermentioned determination method of RP-HPLC,
which could determine the trace concentration of CCNU 300 ng=ml.
MATERIALS
Instruments: WATERS 515 HPLC pump, WATERS 996 Photodiode
Array Detector; AUTOSCIENCE vacuum pump; Air bath oscillator.
Reagents: CCNU, Shanghai No. 12 Pharmaceutical Corporation;
Acetonitrile, methanol, and methylene dichloride, HPLC grade; double
distilled water.
Chromatograph conditions: Stainless steel C18 5 mm chromatography
column, 250mm 4.6mm; mobile phase: Acetonitrile=H2O (55=45); flow
speed: 1.0ml=min; detection wavelength: 254 nm; injection volume: 20 ml.
METHODS AND RESULTS
1. Animal Experiments
The mice (weight 1820 g, ,< half and half) were separated into 5 groups
(12 mice in every group) randomly; they were the control group (N.S.),
the CCNU1, CCNU2, CCNU3, and CCNU4 group. The mice were
planted S180 sarcoma i.h at oxter, when the sarcoma growed to proper
size, one group of the mice were administered with N.S. po, and the other
four groups of the mice were administered with CCNU 42mg=kg po,
then we killed the mice and peeled off the tumor, mensurated the weight
of tumor, kept them in freezer. The CCNU1, CCNU2, CCNU3, and
CCNU4 group was the group of mice that was killed at the No. 1, 2,
3, and 4 day after administration, respectively.
2. Chromatography Behavior of CCNU and Standard Curve
Weighed 5.0mg CCNU precisely, dissolved it in mobile phase, prepared
standard solution whose concentrations are 15.68 mg=ml, 7.84 mg=ml,
3.92 mg=ml, 1.96 mg=ml, and 0.98 mg=ml, then determined their absorption
spectrum, we could get the linear relation from peak area (Y) and concen-
tration (X):
Y ¼ 208:98Xþ 0:42 r ¼ 0:9999
Figure 1 is the standard curve of CCNU. Figure 2 is the chromato-
graphy behavior of CCNU. CCNU retention time is 6.2–6.3 minutes.






































































3. Assay of CCNU in Tumor
Ground the tumor tissue with 0.1mol=L PB solution (Phosphate buffer
solution, pH7.4), and got the 20% tissue suspension. Added 10mL aether
and had enough extraction, then the mixed liquid was filtered and kept
the filtrate. Extracted this filtrate with separating funnel, the aether layer
solution was super-speed centrifugated (15000 rpm, 20min, 4C), the
aether of the supernatant was vaporized at 40C, then dissolved the solid
with 0.2mL methanol, filtrated the solution with millipore filter, and
injected 20 ml filtrate into the HPLC. According to the peak area of
20 ml solution, we could get the concentration of the CCNU solution.
Table 1 is the result of the CCNU content in the tumor tissue.
Figure 2. The chromatography behavior of CCNU.
Figure 1. The standard curve of CCNU.






































































4. Recovery Test of the Determination Method
Weighed 2.0mg CCNU precisely, dissolved it in mobile phase, prepared
the solution whose concentration was 2.0 mg=ml. Added this solution
250 ml into 20% tumor tissue suspension (0.1mol=L PB solution, pH7.4,
without CCNU in the suspension) respectively, processed them by the
above mentioned method, and the recovery of the method was 68.64%.
Table 2 is the result of the recovery test.
5. Repetition Test of the Determination Method
Injected the 2.0 mg=ml CCNU standard solution repeatedly, the RSD of
the repetition test was 0.32%. Table 2 is the result of the repetition test.
6. Lower Limit of the Determination Method
Injected the CCNU standard solution into HPLC; the lower limit of the
determination method was 300 ng=ml.
DISCUSSIONS
CCNU had good stabilization in mobile phase, there was only one little
peak before the CCNU peak on the liquid chromatograph after the
CCNU solution was deposited for 48 hours. For the sake of lessening
the error, we should determine the standard curve as quickly as possible,
inject the samples immediately after the extraction of CCNU. We didn’t
study the metabolism and degradation of CCNU in vivo, and didn’t
Table 1. Assay of CCNU in tumor (n ¼ 12)
Group Weight of tumor (mg) Concentration (mg=ml) Content ( mg=g)
CCNU1 1325 1.434 0.216
CCNU2 1341 4.879 0.728
CCNU3 817 2.557 0.625
CCNU4 381 0.579 0.116






ratio (%) Times (n) RSD (%)
0.5 0.344 68.64 5 0.32






































































determine its metabolites. On conditions that study the pharmacokinetics
of CCNU, we should define and determine the metabolites of CCNU.
Though CCNU could be transformed to some metabolites in the
tissue of mice, just analyzing the content of CCNU could indicate the dis-
tribution conditions in vivo. Furthermore, for lessening the error of
determination, we should peel off and freeze the tumor tissue as quickly
as possible.
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